

REMARKS:

Claims 1-8 are pending in the subject application.

The Examiner objected to claim 4. A comma has been added after "benalaxyil" as requested.

The Examiner rejected claims 1-8 under 35 U.S.C. 112, second paragraph, as being indefinite. In response, claim 1 has been clarified such that "a first composition" and "a second composition" have been amended to recite "a first compound" and "a second compound."

As no art has been cited against the claims, and in view of the amendment to claim 1 in response to the indefiniteness rejection, all claims are believed to be allowable.

Except for the fee due for a two-month petition for an extension of time, no fee is believed to be due with this response. Should there be any unforeseen costs, please charge our Deposit Account No. 17-0055.

Respectfully submitted,

Quarles & Brady LLP



Gavin J. Milczarek-Desai  
Reg. No. 45,801

(520) 770-8716 phone  
(520) 770-2235 fax